PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(10): e13439.
Published online 2010 October 15. doi:  10.1371/journal.pone.0013439
PMCID: PMC2955541

Transgenic Expression of P1A Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis

Chi-Shan Li,#1,5 Chong Chen,#1 Pan Zheng,1,3,4,* and Yang Liu1,2,3,*
Sujit Basu, Editor

Abstract

P1A is the first known tumor rejection antigen. It is expressed in embryonic stem cells and multiple tumors but is silent in adult tissues except for the testis and placenta. Therefore, P1A represents a prototype for onco-fetal antigens. To test the potential function of P1A in tumorigenesis, we used a transgenic mouse expressing P1A in lymphoid cells. We observed that immunodeficient host P1A transgenic mice developed thymic tumors after 7 months of age and had shorter survival rates compared to control groups. Most of the 7 examined tumors displayed B cell lineage markers. The P1A transgenic bone marrow cells had higher proliferation ability and more potential progenitors compared to control bone marrow cells. To our knowledge, our data provided the first example that onco-fetal antigen can promote tumorigenesis.

Introduction

By definition, tumor antigens were identified because cancer-reactive lymphocytes could recognize these proteins [1]. An interesting but still poorly understood phenomenon is that many tumor antigens are also abundantly expressed at early stages of embryogenesis. These antigens are termed onco-fetal antigens. Theoretically, these antigens might be useful for cancer immune therapy, since they are highly expressed on tumor cells but absent in the adult host with the exception of placenta and testis. In addition, the expression of these types of antigens on tumor cells may reflect the fact that cancer may resemble the biological properties of embryonic cells. One key issue is whether the onco-fetal antigens play a significant role in cell differentiation or proliferation, since tumor and embryonic cells share some biological properties.

P1A is a prototype of onco-fetal antigens. Only recently, the P1A gene has been mapped to the X-chromosome (Mouse Genome Informatics, ID 98818). Identification of P1A as a tumor rejection antigen marked an important breakthrough in tumor immunology as it was the first tumor antigen known to be recognized by cytotoxic T cells [2]. P1A was first identified in the mastocytoma P815 cell line which was derived from DBA/2 mice after exposure to methylcholantrene [3]. Later, studies also found that P1A was expressed in several tumors such as Meth A sarcoma and J558 plasmacytoma [4]. P1A is highly expressed in the testis and placenta [5]. The levels of P1A mRNA in the testis and placenta are around 10–20% and 150–200% of mastocytoma P815, respectively [5]. In addition, P1A mRNA was detectable in spleen, lung, liver and thymus by reverse transcription- polymerase chain reaction (RT-PCR), although the relative abundance of P1A mRNA in these tissues was much lower than that found in J558 tumor cells [6]. Here, we show that P1A is also expressed in mouse R1 embryonic stem (ES) cells.

The function of P1A is unknown to date. Since tumor cells, germ cells and stem cells have the capacity to differentiate and proliferate, it is possible that P1A may be involved in a particular state of cell differentiation and growth regulation. Therefore, to seek the function of onco-fetal antigens, we used P1A as a model. In this paper, we found that our transgenic mouse line, which over-expresses tumor antigen P1A in lymphoid cells, developed a variety of tumors after 7 months. The results from this study suggest that P1A is involved in tumorigenesis.

Results

P1A express in embryonic stem cells and P1A transgenic (P1A Tg) thymus

Our P1A transgene contained the enhancer of the immunoglobulin heavy chain gene (Eμ), the mb-1 promoter, followed by P1A open reading frame, an ID2 gene, and an SV40 polyadenylation signal (Figure 1A). P1A was under the control of the mb-1 promoter, which is expressed specifically in B cells from the progenitor to mature stages [7]. In addition, the enhancer of Eμ has been shown to promote transgene expression in B and T lymphoid cells [8], [9], [10], [11], [12]. Thus, our P1A Tg mice can express P1A in lymphoid cells. P1A protein was detectable by Western blot in P1A Tg thymus by the anti-P1A antibody against the C-terminus of the P1A protein, however it was not detected in P1A Tg spleen even with much more protein loaded (Figure 1B). As shown in Figure 1B, P1A protein level was highest in J558 plasmacytoma cells followed by mouse R1 embryonic stem cells and then the testis, according to the actin loading amount.

Figure 1
Expression of P1A.

P1A Tg mice developed thymic tumors

To increase tumor susceptibility, we crossed the P1A transgene to Rag2−/− background which is immune-deficient due to lack of T and B lymphocytes. We observed that 19 out of 49 P1A Tg mice in Rag2-deficient background developed thymic lymphoma after 7 months of age. The Rag2−/−P1ATg mice had enlarged thymuses compared to control mice (Figure 2A). In addition to the thymus, the spleen was also enlarged (data not shown). Moreover, tumor infiltration into target organs, including liver and lung, were also widespread (data not shown). In addition, when using tumor incidence as a survival end point, P1A Tg mice in immunodeficient background (Rag2−/−) had significant shorter survival rates due to the tumor formation compared to control groups (p = 0.0004, Figure 2B). A trend of increased tumor was also noted in WT background, although the increase was not statistically significant (p = 0.1157, Figure 2C).

Figure 2
P1A Tg mice developed tumors.

In order to determine the lineages of the tumors, we analyzed the cell surface markers of the thymic tumors. As shown in Figure 3, only 1 of the 7 tumors analyzed expressed significant levels of CD4 and CD8. In contrast the majority of tumors expression markers of non-T lineages, including that of B cells (B220+), plasmacytoid dendritic cells (B220+CD11c+) , myeloid cells (B220+Gr1+CD11b+). The result is consistent with the fact that Rag2 deficiency results in the thymocyte differentiation being blocked before they can reach the CD4+CD8+ stage [13]. It is noteworthy that all but one of tumors expresses B220, a marker for the B cell lineage.

Figure 3
Heterogeneity of tumors in individual mouse.

P1A Tg bone marrow (BM) cells exhibit higher proliferation and more hematopoietic colony forming units

We determined P1A Tg BM cell proliferation ability by BrdU incorporation assay. BrdU is an analog of the DNA precursor thymidine. The proliferating cells will incorporate BrdU into their DNA. The amount of BrdU in the DNA of cells can be detected with specific anti-BrdU fluorescent antibodies followed by flow cytometry. After 24 hours of labeling BrdU in vivo, we analyzed the BrdU incorporation rate by flow cytometry. Forty-six percent of BM cells from wild-type (WT) control mice were BrdU positive. However, the P1A Tg mice had a significant increase in the proportion of BrdU-positive BM cells both in immunocompromised (P1A+Rag2+/+) and immunodeficient (P1A+Rag2−/−) backgrounds compared to WT mice (p = 0.02 and 0.03, respectively, Figure 4 AB).

Figure 4
Enhanced proliferation and progenitor activity of P1A Tg bone marrow.

We also cultured P1A Tg BM cells and control cells in methylcellulose based medium to quantify potential progenitors in vitro. The hematopoietic progenitors were able to proliferate and differentiate, resulting in the generation of mature cells. Colony-forming units (CFUs) were measured in semi-solid media with appropriate cytokines. We found P1A Tg BM had much higher CFU compared to control BM. The increase was more obvious in the second round culture (Figure 4C). According to their morphology, the increases of colony number in all colony types, including BFU-E (burst-forming unit-erythroid), CFU-G (colony-forming unit granulocyte), CFU-M (colony-forming unit macrophage) and CFU-GM (colony-forming unit granulocyte macrophage), were seen in P1A Tg BM by inverted microscopy (Figure 4D).

Discussion

P1A, the first identified tumor rejection antigen, is presented to cytotoxic T lymphocytes by bound to major histocompatibility complex (MHC) class I molecules on the tumor cell surface [14]. Our data on the expression of P1A in tumor cells and its presence in embryonic stem cells and testis indicated that P1A is an onco-fetal antigen. In testis, it has been shown that P1A expression is restricted to spermatogonia cells which are MHC class I negative cells [5]. In addition, MHC class I molecules are not detected in the undifferentiated ES cells by FACS or immunofluorescence staining in ES cells [15]. Hence, the low to no expression of cell-surface MHC class I on spermatogonia and ES cells suggests that they are immune privilege. Therefore, these normal cells expressing P1A antigen are compromised in the immune system due to low MHC class I expression, but not tumor cells.

The phenotypes of P1A Tg mice suggested that onco-fetal antigen P1A was indeed involved in tumorigenesis. First, we observed that P1A Tg mice developed thymic leukemia after 7 months of age, particularly in immunocompromised mice. Second, we demonstrated higher BrdU incorporation in P1A Tg BM cells compared to WT cells in vivo. Third, there was more CFU from P1A Tg BM compared to control in vitro. To our knowledge, this is the first evidence that P1A may promote tumorigenesis, and the first example that onco-fetal antigen can be involved in tumorigenesis.

Mice with inactivated Rag2 cannot rearrange lymphocyte antigen receptors and therefore lack peripheral T cells and B cells [13], [16]. In thymus, after TCR-β gene rearrangement, the CD4CD8 double negative cells differentiate into CD4+CD8+ double positive thymocytes which are selected to single-positive cells (CD4 or CD8) following TCR-α rearrangement. As a result, T cell development in Rag2-deficient thymus is arrested prior to the CD4+CD8+ stage. The appearance of a thymic tumor at CD4+CD8+ stage suggest that transformation of T cells may have resulted in expression of the CD4 and CD8 molecules. The role for P1A in the process is unknown. Likewise, B cell development in the Rag2-deficient mice is blocked at the pro-B cell stage which could express cell surface marker, B220 [13], [16]. The widespread expression of B220 among the tumors is therefore anticipated. However, the occurrence of thymic tumor in all tumor-bearing mice deserves consideration. CD4CD8 double negative thymocytes contain a mixture of lineage-committed progenitors which can reconstitute T, B, NK and dendritic cell lineages [17], [18], [19]. Our transgene P1A was expressed during hematopoietic progenitor development; therefore, any stage of cells may be the targets of the transformation or immortalization process by P1A activation. The heterogeneity was probably the result of tumor initiation at different stage of progenitor cell development. Hence, P1A induced tumorigenesis is not stage-specific and resulted in various thymic tumor types in mice, such as B cells (B220+), plasmacytoid dendritic cells (B220+CD11c+) and myeloid cells (Gr1+CD11b+).

Several clinical studies have indicated that the frequency of cancer in immunodeficient background is more frequent [20], [21], [22]. For example, children with immunodeficiency are at a higher risk of malignancy, such as lymphomas and leukemias [23]. Therefore, the immune system, including innate and adaptive immunity, is able to inhibit the tumor development and eradicate the tumors already established [21]. A similar phenomenon was also shown in animal models. For example, after subcutaneous injection of the chemical carcinogen methylcholanthrene, Rag2−/− background mice developed higher frequency of sarcomas compared to the strain-matched controls [24]. Our data indicated that thymic tumors occurred more frequently in the Rag2-deficient background and the immune system of a normal immunocompetent mouse may be able to eliminate the P1A-induced tumor.

Taken together, P1A induced tumorigenesis and resulted in various thymic tumor types in mice. Our present work demonstrated that onco-fetal antigen P1A was associated with the transformed phenotype in P1A transgenic mice. Therefore, expression of onco-fetal antigens may be biologically relevant to tumorigenesis. Further studies are required to dissect the mechanisms of the process of oncogenesis by P1A.

Materials and Methods

Cell lines and experimental animals

Mouse plasmacytoma J558 from ATCC were cultured in RPMI 1640 medium containing 5% fetal bovine serum (FBS) and 100 µg/ml penicillin and streptomycin. Murine R1 ES cells were co-cultured with mouse embryonic fibroblast (MEF) cells in DMEM medium containing 15% FBS, 0.1 mM β-mercaptoethanol, 103 u/ml leukemia inhibitory factor, and 4 mM glutamine. Rag2−/− mice were obtained from the Taconic Laboratories (Terrytown, NY). P1A transgenic (P1A Tg) mice were as described previously [6], [9]. The transgene has been crossed to BALB/c for more than 10 generations, and was crossed to BALB/c Rag2−/− background for the current studies. P1A+Rag2−/− mice in this study came from 7 breeding pairs. All animal experiments were conducted in accordance with accepted standards of animal care and approved by the Institutional Animal Care and Use Committee of University of Michigan.

Western blot analysis

Samples of mouse tissues or cells were lysed in protein lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40) and protease inhibitor cocktails (Sigma) including 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, aprotinin, bestatin, E-64, leupeptin and pepstain A were added. Cell lysates were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride (PVDF) membranes, and incubated with anti-P1A rabbit antibody specific for the peptide sequence, YEMGNPDGFSP (Genemed Synthesis, 1[ratio]500 dilution) or anti-actin mouse antibody (Sigma, 1[ratio]5000 dilution). Anti-rabbit or anti-mouse IgG horseradish peroxidase–linked antibody at 1[ratio]3500 dilutions (GE Healthcare) was used as secondary antibodies. Antibodies were detected with chemiluminescence reaction using the enhanced chemiluminescence kit (Amersham Biosciences) and visualization with exposure to film.

Flow cytometric analysis

P1A transgenic mice were sacrificed when moribund. Thymus and spleen tissue were homogenized and passed through a cell strainer (BD Biosciences) to generate a single-cell suspension. Cells were stained in phosphate-buffered saline plus 2% FBS for 20 minutes on ice with the following monoclonal antibodies at a 1[ratio]200 dilution, CD4, CD8, B220, CD11c, Gr1, and CD11b (BD Biosciences). Cells were subsequently analyzed by BD LSR II Flow Cytometer.

Bromodeoxyuridine (BrdU) incorporation assay

Mice were injected intraperitoneally with BrdU (100 mg/kg, Sigma-Aldrich). Then, mice were given BrdU water (1 mg/ml) for 24 hours before sacrifice. BrdU staining kit (BD Biosciences) was used according to the manufacturer's instructions. Each group had three mice from two independent experiments.

Colony-forming cell assay

Bone marrow cells were isolated from the femur and tibia of mice. Bone marrow cells (1×104) were plated in MethoCult® methylcellulose-based media (StemCell Technologies) per 35mm dish and incubated at 37°C, 5% CO2. After 12 days culture, colony number and morphology was counted using inverted microscope. Bone marrow cells were from one Rag2−/− and one P1A+Rag2−/− mouse and each group was tested in triplicates from a single experiment.

Statistics

The differences in mouse survival rates were calculated by Kaplan-Meier analysis. Other data were analyzed using 2-tailed unpaired Student's t-test. Differences of p<0.05 were considered statistically significant. All statistics were performed using GraphPad Prizm, version 5 (GraphPad Software, San Diego, CA).

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This study is supported by the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725–729. [PMC free article] [PubMed]
2. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med. 1991;173:1373–1384. [PMC free article] [PubMed]
3. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med. 1983;157:1040–1052. [PMC free article] [PubMed]
4. Ramarathinam L, Sarma S, Maric M, Zhao M, Yang G, et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol. 1995;155:5323–5329. [PubMed]
5. Uyttenhove C, Godfraind C, Lethe B, Amar-Costesec A, Renauld JC, et al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997;70:349–356. [PubMed]
6. Sarma S, Guo Y, Guilloux Y, Lee C, Bai XF, et al. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med. 1999;189:811–820. [PMC free article] [PubMed]
7. Sakaguchi N, Kashiwamura S, Kimoto M, Thalmann P, Melchers F. B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties. Embo J. 1988;7:3457–3464. [PubMed]
8. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–538. [PubMed]
9. Rosenbaum H, Harris AW, Bath ML, McNeall J, Webb E, et al. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. Embo J. 1990;9:897–905. [PubMed]
10. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. Embo J. 1989;8:749–755. [PubMed]
11. Sun XH. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell. 1994;79:893–900. [PubMed]
12. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56:673–682. [PubMed]
13. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68:855–867. [PubMed]
14. Van den Eynde B, Mazarguil H, Lethe B, Laval F, Gairin JE. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur J Immunol. 1994;24:2740–2745. [PubMed]
15. Magliocca JF, Held IK, Odorico JS. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev. 2006;15:707–717. [PubMed]
16. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869–877. [PubMed]
17. Wu L, Antica M, Johnson GR, Scollay R, Shortman K. Developmental potential of the earliest precursor cells from the adult mouse thymus. J Exp Med. 1991;174:1617–1627. [PMC free article] [PubMed]
18. Shortman K, Wu L. Early T lymphocyte progenitors. Annu Rev Immunol. 1996;14:29–47. [PubMed]
19. Kawamoto H, Ohmura K, Katsura Y. Presence of progenitors restricted to T, B, or myeloid lineage, but absence of multipotent stem cells, in the murine fetal thymus. J Immunol. 1998;161:3799–3802. [PubMed]
20. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prev. 1994;18:241–252. [PubMed]
21. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148. [PubMed]
22. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol. 2003;3:1061–1071. [PubMed]
23. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr. 1995;126:1–10. [PubMed]
24. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science